Apatinib, a small-molecule tyrosine kinase inhibitor, primarily targets VEGFR2 but exhibits even stronger inhibition of c-Kit, potentially enhancing its anti-tumor effects through dual angiogenic and stromal modulation (6, 7). The gene discussed is KDR; the disease is neoplasm.